Market Access Academy

  • Executive
  • LSE Health
  • Application code EE910
  • Starting 2020
  • Short course: Open
  • Location: Houghton Street, London

Created in collaboration with The Boston Consulting Group (BCG) and leading pharmaceutical companies from around the world, this intensive course connects pharmaceutical management with advanced knowledge and strategies in market access.

5 day intensive programme running 7 - 11 September and 14 - 18 September 2020  

Please note we are now fully booked for the programme running 7 - 11 September and we are no longer accepting applications. If you would like to be added onto the waiting list, please email and we will contact you if there is any availability.

The Market Access Academy is aimed at present and future Access Leaders within the pharmaceutical industry. Based on key business needs, it will provide participants with a common grounding in market access, training in representative decision-making across the product life-cycle, and strategies to adapt to a rapidly changing industry landscape.

We have a highly developed programme of lectures, case studies, workshops, and notable guest speakers. This bespoke selection provides technical experts - as well as those from other functions - the tools to understand the market access environment, plan strategy, and optimise access and value.

What will Access Leaders gain?

  • A common grounding in market access.
  • Training in representative decision-making across the product life-cycle.
  • Strategies to adapt to a changing landscape.
  • Five days of lectures, case studies, workshops and VIP guest speakers.

Tuition Fee:

  • Market Access Roundtable Members: £6,995
  • Non-Market Access Roundtable Members: £7,295

Includes all LSE tuition, course materials, daily lunches, and networking events. You will also be awarded an LSE certificate of completion at the end of the five days.

Part of LSE Executive Education Courses

Programme details

Programme structure

The Academy is taught over five days and is a mix of lectures, panel speakers, and interactive case studies:

Module 1: Understanding access, drivers, and barriers
Learning objectives: Understanding of key leverage points (evidence, non-evidence) used to optimise P&R outcomes across different in-scope markets and TAs.

Module 2: Defining an integrated evidence package
Learning objectives: Navigating challenges and trade-offs (internal and external) for successful decision-making in evidence-generation planning and synthesis.

Module 3: Creating a receptive access environment
Learning objectives: Identifying key relevant stakeholders and assessing different non-evidence access levers enabling Access Leaders to develop a broader stakeholder engagement plan beyond HTAs and payers. This module focuses on the importance of market access stakeholders, the role of patient organisations, and utilising collaborative negotiations to realise success.

Module 4: Optimising access and value
Learning objectives: Developing a successful strategic P&R approach by understanding the overall option space, trade-offs and most relevant tools. The module provides participants with the technical functional expertise needed to develop P&R strategies and then expands on how to build an effective pricing strategy in three parts, with focus on the payer and industry perspectives.

Module 5: Managing access strategy and execution
Learning objectives: Understanding the behaviours and tools of successful cross-functional Access Leaders, as seen by executives and senior internal clients.

 View a sample timetable of the week >>

Course outcomes

During the course's highly interactive five days, participants will:

  • Learn representative decision-making as Access Leaders, including how to frame and address business requirements/issues.
  • Understand the functional, technical access competencies (policy, evidence generation etc.) and the roles they play in business decisions.
  • Deepen understanding of evolving access-relevant trends and access landscape/environment.
  • Network with pharmaceutical executives, industry professionals from Health Technology Assessment (HTA) bodies, key policy makers and more.


Faculty and guest speakers

The course will be taught by:

Elias Mossialos is Brian Abel-Smith Professor of Health Policy, Head of Department of Health Policy and Director of LSE Health. Professor Mossialos founded LSE Health in 1996. Learn more here

Dr Panos Kanavos is Associate Professor of International Health Policy in the Department of Health Policy at London School of Economics and Political Science, Deputy Director at LSE Health and Programme Director of the Medical Technology Research Group (MTRG). Read more here

Professor Alistair McGuire is Chair of Health Economics in the Department of Health Policy. Prior to this he was Professor of Economics at City University, London after being a tutor in Economics at the University of Oxford. Read more here

Allan is Professor of Epidemiology and Medical Statistics, CRUK Cancer Trials Centre at UCL. Read more here

VIP guest speakers from past courses

  • Nigel Edwards, Chief Executive, Nuffield Health
  • Leeza Osipenko, Associate Director, Scientific Advice, National Institute for Health and Care Excellence (NICE)
  • Dr Richard Torbett, Executive Director - Commercial Policy: UK and International, Association of the British Pharmaceutical Industry (ABPI)
  • Robert Madelin, Senior Advisor for Innovation, European Political Strategy Centre (EPSC), United Kingdom
  • Francis Arickx, Institut National d'Assurance Maladie-Invalidité (INAMI), Belgium
  • Sheela Upadhyaya, Associate Director - Highly Specialised Technologies, NICE, United Kingdom
  • Finn Børlum Kristensen, Managing Director - Science & Policy, Hilleroed, Denmark


The London School of Economics and Political Science (LSE) and The Boston Consulting Group (BCG) have partnered with AbbVie, AstraZeneca, Amgen, Bayer, Eli Lilly, Janssen, Merck, Pfizer, Roche, Sanofi, Takeda, UCB, and members of the BCG Market Access Roundtable, to create Market Access Academy, the first collaborative market access management development programme.

The Academy has been jointly developed by:

  • Latif Akintade, Vice President, Head of Global Market Access, AbbVie
  • Indranil Bagchi, Senior Vice President and Head, Global Value & Access, Novartis
  • Wolfgang Berger, Head of Global Pricing & Market Access Neuroscience, Roche
  • Carmelo Formica, Former Vice President, Head of Global Market Access, Takeda
  • David Greber, Partner and Managing Director, The Boston Consulting Group
  • Jens Grueger, Head Global Pricing & Market Access, Roche
  • Sophie Janssens, Vice President and Global head Real World Evidence, UCB
  • Andrew Karazim, Senior Director, Global Pricing, Reimbursement and Access, Eli Lilly
  • Jonathan Plumb, Head, Global Real-World Data & Evidence Sciences, UCB
  • Herb Riband, Vice President Value Access & Policy, Amgen
  • Anne-Toni Rodgers, Former Head of Operations, Global Payer Evidence and Pricing, AstraZeneca
  • Michael Steelman, Vice President, Head of Global Pricing, Sanofi
  • Ludwig Steindl, Head Market Access Pulmonology and Innovative Women's Health Care, Bayer
  • Karin Steinmann, Director Value Access & Policy Europe, Amgen
  • Koen Torfs, Vice President Global Reimbursement and Real World Evidence, Janssen
  • Srikant Vaidyanathan, Partner and Managing Director, The Boston Consulting Group

Entry requirements

Executive Education Courses are taught to the School's high standard and are therefore academically rigorous. Participants are expected to be fluent in English, with a good undergraduate degree in a relevant subject. 

The Market Access Academy is tailored towards access new starters. Our target participant profile is an individual who meets the following criteria:

  • Minimum of five years’ experience post-university.
  • Leadership experience in other functions, with a look to gain Access exposure.
  • Limited/or very specific Access experience, which lacks the broader view.
  • Recently became (<1 year), or will become, Global Access Leads in the near future.
  • Fluency in English

More information about LSE Executive Education Courses.


Testimonials from the BCG Market Access Roundtable

  • Karin Steinmann, Director Value Access & Policy Europe, Amgen
  • “The industry needs people who understand market access issues and possess key competencies and experience in this area. This is critical to ensuring that patients can benefit from the latest and most innovative therapies. These competencies go beyond mere technical skills – they include a deep understanding of patient issues and how healthcare systems work, an ability to develop a professional relationship with all stakeholders, and a passion to develop effective, sustainable solutions that deliver benefit to the patient and true value to healthcare systems. I believe that LSE Health - Market Access Academy, which has been developed in close collaboration with a number of stakeholders, offers a deep learning experience for the Market Access Leaders of tomorrow.”
  • Anne-Toni Rodgers, Former Head of Operations, Global Payer Evidence and Pricing, AstraZeneca
  • "Market Access is now considered a core capability for any commercial lead – whether launching a product or planning a move to managing a market. LSE Health - Market Access Academy has been developed by Industry Leaders for the Industry – it is a must for anyone who is serious about their career development."
  • Indranil Bagchi, Former Vice President, Head of Payer Insights and Access, Pfizer
  • “Demonstrating value, and thereby ensuring patients worldwide have access to lifesaving medicines, has never been more critical; it is important for Market Access colleagues to stay abreast of the latest trends and remain skilled in the required competencies, which is what this course aims to do.”
  • Mike Steelman, Vice President, Head of Global Pricing, Sanofi
  • "The importance of Market Access is at an all-time high in the pharmaceutical industry. Each and every day we are challenged to explain the value of our medicines to public and private payers who are faced with budgetary constraints. Taking these conversations from price to value are at the core of the competencies needed in Market Access, which include deep healthcare system knowledge, an understanding of payer evidence generation, access strategy and innovative pricing solutions. LSE Health - Market Access Academy addresses these issues in a unique mixture of training from the academic, payer, and industry perspective. High potential colleagues interested in gaining deeper Market Access knowledge will benefit from this intense one-week course."

Testimonials from participants

  • Daniel Messias Campos Alves, Abbvie, Senior Manager, Global Market Access & Pricing
  • "The Access Academy was an excellent opportunity for me to broaden my access skills. The cases are very well designed and can give you a good idea of how things work in a product development and strategy, more broadly speaking. In addition, the Evidence sessions are great, and will help you to understand how HTA agencies think, especially at a European level."
  • Martial Bouillon, Hoffman La-Roche, Corporate Finance Accounting Manager
  • "I found the LSE Health - Market Access Academy a great and very impactful course. Being relatively new in the field, the course helped me to get an overall view and comprehensive understanding of the most relevant access topics, from barriers and opportunities in the environment to interpretation of clinical studies, as well as definition of evidence packages, and definition of pricing strategy and policy. I also enjoyed the mix of lectures, cases studies and interactions with professionals from many pharma companies and BCG."
  • Thibault de Chalus, Amgen, Senior Pipeline Manager
  • “With participants coming from all over the world (China and Japan, US, Europe), we had the occasion to exchange extensively on differences and similarities across countries for HTA & pricing discussions. For me, this course was a great opportunity to understand impact of market access on early development products: what trade-offs to consider during market access discussions, what evidence to generate during early phases, how to influence market access landscape before market approval. Discussing with colleagues from other companies was a good way to better understand ongoing trends in access: place of European HTA evaluation, cost-effectiveness questions in the US.”

Request a prospectus

  • Name
  • Address

Register your interest

  • Name

Speak to Admissions

Content to be supplied